Evidence map›Paper›PMID 35136154›Full record

ArticleScientific reports2022

Development and validation of a high throughput SARS-CoV-2 whole genome sequencing workflow in a clinical laboratory.

Sun Hee Rosenthal, Anna Gerasimova, Rolando Ruiz-Vega, Kayla Livingston, Ron M Kagan, Yan Liu, Ben Anderson, Renius Owen, Laurence Bernstein, Alla Smolgovsky and 5 more

Open access · goldAbstract readValidation Study
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. A comparison of five Illumina, Ion Torrent, and nanopore sequencing technology-based approaches for whole genome sequencing of SARS-CoV-2.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023
    Article
  11. Article
  12. The origins of COVID-19 pandemic: A brief overview.Transboundary and emerging diseases · 2022
    Review
  13. Rapid and Accurate Identification of SARS-CoV-2 Variants Using Real Time PCR Assays.Frontiers in cellular and infection microbiology · 2022
    Article
  14. Review
  15. High-throughput and automated screening for COVID-19.Frontiers in medical technology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Sun Hee Rosenthal *Quest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Anna Gerasimova *Quest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Rolando Ruiz-Vega *Quest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Kayla Livingston *Quest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Ron M KaganQuest Diagnostics, San Juan Capistrano, CA, 92675, USA. Ron.M.Kagan@questdiagnostics.com.
Yan LiuQuest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Ben AndersonQuest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Renius OwenQuest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Laurence BernsteinQuest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Alla SmolgovskyQuest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Dong XuQuest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Rebecca ChenQuest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Andrew GrupeQuest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Pranoot TanpaiboonQuest Diagnostics, San Juan Capistrano, CA, 92675, USA.
Felicitas LacbawanQuest Diagnostics, San Juan Capistrano, CA, 92675, USA. Felicitas.L.Lacbawan@questdiagnostics.com.
Quest Diagnostics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monitoring new mutations in SARS-CoV-2 provides crucial information for identifying diagnostic and therapeutic targets and important insights to achieve a more effective COVID-19 control strategy. Next generation sequencing (NGS) technologies have been widely used for whole genome sequencing (WGS) of SARS-CoV-2. While various NGS methods have been reported, one chief limitation has been the complexity of the workflow, limiting the scalability. Here, we overcome this limitation by designing a laboratory workflow optimized for high-throughput studies. The workflow utilizes modified ARTIC network v3 primers for SARS-CoV-2 whole genome amplification. NGS libraries were prepared by a 2-step PCR method, similar to a previously reported tailed PCR method, with further optimizations to improve amplicon balance, to minimize amplicon dropout for viral genomes harboring primer-binding site mutation(s), and to integrate robotic liquid handlers. Validation studies demonstrated that the optimized workflow can process up to 2688 samples in a single sequencing run without compromising sensitivity and accuracy and with fewer amplicon dropout events compared to the standard ARTIC protocol. We additionally report results for over 65,000 SARS-CoV-2 whole genome sequences from clinical specimens collected in the United States between January and September of 2021, as part of an ongoing national genomics surveillance effort.

Indexed as

Genome, ViralMutationWhole Genome SequencingCOVID-19HumansSARS-CoV-2

Identifiers

PMID35136154
PMCPMC8826425
OpenAlexW4210936403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.